Drug Pipeline News

Daré Bioscience has announced positive results from a phase 2b trial analyzing the safety and efficacy of sildenafil cream, 3.6% in women with female sexual arousal disorder.

Genevieve Neal-Perry, MD, PhD, talks about the recent approval of fezolinetant (Veozah; Astellas Pharma) and her latest phase 3 research presented at the 2023 ACOG Annual Clinical and Scientific Meeting.

Fezolinetant (Veozah; Astellas Pharma) is now the first neurokinin 3 receptor antagonist approved for the treatment of vasomotor symptoms associated with menopause.

In a unanimous vote, norgestrel (Opill; HRA Pharma) has been backed by an FDA advisory panel as an over-the-counter birth control pill.

With an FDA approval, it would be the first new class of oral antibiotics for uncomplicated urinary tract infections (uUTI) in over 20 years.

In a recent phase 1 trial, DARE-HRT1 showed positive safety and acceptability results for treating moderate-to-severe vasomotor symptoms in postmenopausal women.

Following voluntary market withdrawal from Covis Pharma, the FDA has decided to withdraw the approval of Makena and its generics for reducing the risk of preterm birth.

Visby Medical has announced its second generation point of care test for detecting sexually transmitted diseases in women has received 510(k) clearance and a CLIA waiver from the FDA.

Newly published data from a phase 3 study demonstrate the safety and efficacy of fezolinetant (Astellas) for treatment of VMS due to menopause.

Covis, the manufacturer of the controversial preterm birth prevention drug Makena, has announced it will voluntarily withdraw the drug from the market after recommendations from the Center for Drug Evaluation and Research.

The therapy, bepirovirsen, is an antisense oligonucleotide that targets all Hepatitis B (HBV) messenger RNAs, and the company is hoping it will become a functional cure.

Individuals that did not respond had a lower percentage of naïve T cells compared to responders, while responders had a lower percentage of Th2 and CD4 central memory subsets before vaccination.

The wearable device received its original FDA go-ahead in 2019, and has since demonstrated effectiveness in preventive and acute care for migraine treatment in adolescents and adults.

The federal agency set a Prescription Drug User Fee Act (PDUFA) action date of August 2023.

Results reported at CROI showed that 2 cohorts of the ongoing, phase 3 DELIVER study that this form of PrEP modality posed no differences in pregnancy and infant outcomes.

A look at contraceptive methods and how they are poised to affect women’s health.

The FDA has granted a regular approval to dostarlimab-gxly (Jemperli; GSK) for adult patients with mismatch repair–deficient, recurrent or advanced endometrial cancer that has progressed on or after a prior platinum-containing regimen in any setting and who are not candidates for curative surgery or radiation.

The US Food and Drug Administration has accepted the Biologics License Application (BLA) for a proposed biosimilar of denosumab (Prolia and Xgeva; Amgen) for treatment of various conditions.

The rare condition can lead to life-threatening anemia in the fetus and currently lacks FDA-approved treatments.

In this interview, Michael Krychman, MD, a community-based gynecologist in Newport Beach, California, takes a look at 2022 advances within the contraceptive space, as well as looks toward the future.

Marco Taglietti, MD, president and CEO of Scynexis, sits with Contemporary OB/GYN® to discuss the recent approval of ibrexafungerp (Brexafemme) for the reduction in incidence of recurrent vulvovaginal candidiasis.

The precision medicine company announced successful completion of its Unyvero urinary tract infection (UTI) clinical trial with promising results and plans for submission to the FDA.

GSK plc has announced positive results for safety and tolerance of dostarlimab (Jemperli; GSK plc) in treating women with endometrial cancer.

Ibrexafungerp (Brexafemme; Scynexis) is now approved for the treatment of vulvovaginal candidiasis and reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC).

This is the first FDA-approved ADC for platinum-resistant disease, according to ImmunoGen.